Drug profile · INN
ivonescimab
ivonescimab is an FDA-listed pharmaceutical active ingredient.
Drug details — ivonescimab
- Class
- —
- Route
- —
- Patents
- 0
- Programs
- 30
- Data quality
- 0.70
Quick answer
ivonescimab is an FDA-listed pharmaceutical active ingredient.
Key facts
Approval history
| Authority | Status | Date |
|---|---|---|
| NMPA | clinical trials | — |
Recent coverage
Pharma bets on PD-1/VEGF bispecifics: Is lung cancer the wrong target?
While many drugmakers are focused on lung cancer for PD-1/VEGF bispecifics, emerging evidence shows the liver may offer higher value. This analysis covers the mechanism, key players, and strategic implications for pharma teams.
ASCO Preview: Akeso's Ivonescimab Under Scrutiny
As Akeso prepares for a plenary presentation at ASCO 2026, ivonescimab's HARMONi-6 overall survival data will be closely watched. This article covers key takeaways, competitive implications, and next milestones for pharma teams and investors.
ASCO Summit: Ivonescimab's China Lung Data Shows Promise, But Global Validation Remains Key
Summit Therapeutics' ivonescimab demonstrated a significant survival benefit in a Chinese lung cancer trial presented at ASCO, yet analysts caution that replicating these results in a broader, global population is crucial for its market potential against established therapies like Keytruda.
ASCO 2026 Preview: Key Data and Trends in Cancer Research
This ASCO preview highlights crucial developments in cancer research, focusing on key data presentations and emerging trends that will shape the oncology landscape. Investors and BD teams should monitor these advancements for strategic insights.
Pipeline programs
Frequently asked questions
What is ivonescimab?
ivonescimab is an FDA-listed pharmaceutical active ingredient.